Myocardial Protection in Minimally Invasive Mitral Valve Surgery: Retrograde Cardioplegia Alone Using Endovascular Coronary Sinus Catheter Compared With Combined Antegrade and Retrograde Cardioplegia.


Journal

Journal of cardiothoracic and vascular anesthesia
ISSN: 1532-8422
Titre abrégé: J Cardiothorac Vasc Anesth
Pays: United States
ID NLM: 9110208

Informations de publication

Date de publication:
May 2019
Historique:
received: 31 05 2018
pubmed: 19 1 2019
medline: 23 8 2019
entrez: 19 1 2019
Statut: ppublish

Résumé

To compare myocardial protection with retrograde cardioplegia alone with antegrade and retrograde cardioplegia in minimally invasive mitral valve surgery (MIMS). Retrospective study. Tertiary care university hospital. The authors studied 97 MIMS patients using retrograde cardioplegia alone and 118 MIMS patients using antegrade and retrograde cardioplegia. The data from patients admitted for MIMS using retrograde cardioplegia (MIMS retro) between 2009 to 2012 were compared with the data from patients undergoing MIMS with antegrade and retrograde cardioplegia (MIMS ante-retro) between 2006 and 2010 (control group). Cardioplegia in the MIMS retro group was delivered solely through an endovascular coronary sinus (CS) catheter positioned under echographic and fluoroscopic guidance. Antegrade and retrograde cardioplegia was used in the MIMS ante-retro group. Data regarding myocardial infarction (MI; creatine kinase Mb, troponin T, electrocardiogram), myocardial function, and hemodynamic stability were collected for comparison. Adequate cardioplegia administration (CS pressure >30 mmHg and asystole) was attained in 74.2% of the patients with retrograde cardioplegia alone. In 23.7% of the patients, the addition of an antegrade cardioplegia was necessary. No difference was observed in the incidence of MI (0 MIMS retro v 1 for MIMS ante-retro, p = 0.3623), difficult separation from cardiopulmonary bypass, and postoperative malignant arrhythmia. No difference was found for maximal creatine kinase Mb (39.1 [28.0-49.1] v 37.9 [28.6-50.9]; p = 0.8299) and for maximal troponin T levels (0.39 [0.27-0.70] v 0.47 [0.32-0.79]; p = 0.1231) for MIMS retro and MIMS ante-retro, respectively. However, lactate levels in the MIMS retro group were significantly lower than in the MIMS ante-retro group (2.1 [1.4-3.05] v 2.4 [1.8-3.3], respectively; p = 0.0453). No difference was observed in duration of intensive care unit stay and death. MIMS retro patients had a shorter hospital stay (7.0 [6.0-8.0] v 8.0 [7.0-9.0] days; p = 0.0003). Retrograde cardioplegia administration alone provided comparable myocardial protection to antegrade and retrograde cardioplegia during MIMS, but was not sufficient to achieve asystole in one-fifth of patients.

Identifiants

pubmed: 30655202
pii: S1053-0770(18)31094-2
doi: 10.1053/j.jvca.2018.11.042
pii:
doi:

Substances chimiques

Cardioplegic Solutions 0

Types de publication

Comparative Study Journal Article

Langues

eng

Pagination

1197-1204

Commentaires et corrections

Type : CommentIn

Informations de copyright

Crown Copyright © 2018. Published by Elsevier Inc. All rights reserved.

Auteurs

Jean-Sebastien Lebon (JS)

Department of Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. Electronic address: lebon034@hotmail.com.

Pierre Couture (P)

Department of Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Melissa Colizza (M)

Department of Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Annik Fortier (A)

Department of Montreal Health Innovations Coordinating Center, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Antoine Rochon (A)

Department of Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Christian Ayoub (C)

Department of Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Georges Desjardins (G)

Department of Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Alain Deschamps (A)

Department of Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Marie-Ève Chamberland (MÈ)

Department of Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Eric Laliberté (E)

Department of Clinical Perfusion, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.

Denis Bouchard (D)

Department of Cardiac Surgery, Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada.

Michel Pellerin (M)

Department of Cardiac Surgery, Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH